The Epstein–Barr Virus (HHV-4) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Epstein–Barr Virus (HHV-4) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Epstein–Barr Virus (HHV-4) Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Epstein–Barr Virus (HHV-4) Infections and features dormant and discontinued products.

GlobalData tracks 76 drugs in development for Epstein–Barr Virus (HHV-4) Infections by 69 companies/universities/institutes. The top development phase for Epstein–Barr Virus (HHV-4) Infections is preclinical with 31 drugs in that stage. The Epstein–Barr Virus (HHV-4) Infections pipeline has 40 drugs in development by companies and 36 by universities/ institutes. Some of the companies in the Epstein–Barr Virus (HHV-4) Infections pipeline products market are: Baylor College of Medicine, Atara Biotherapeutics and Moderna.

The key targets in the Epstein–Barr Virus (HHV-4) Infections pipeline products market include Cells Expressing Latent Membrane Protein 1 (Protein p63 or LMP1), Cells Expressing Latent Membrane Protein 2 (Terminal Protein or LMP2), and Epstein Barr Virus Envelope Glycoprotein GP350 (Membrane Antigen or BLLF1).

The key mechanisms of action in the Epstein–Barr Virus (HHV-4) Infections pipeline product include Cytotoxic To Cells Expressing Latent Membrane Protein 1 (Protein p63 or LMP1) with six drugs in Phase II. The Epstein–Barr Virus (HHV-4) Infections pipeline products include eight routes of administration with the top ROA being Intravenous and 11 key molecule types in the Epstein–Barr Virus (HHV-4) Infections pipeline products market including Cell Therapy, and Small Molecule.

Epstein–Barr Virus (HHV-4) Infections overview

Epstein-Barr virus (EBV), or human herpes virus 4, is a member of the Herpesviridae family. It is one of the most common viruses to cause cancer in humans and is associated with a wide range of human cancers originating from epithelial cells, lymphocytes, and mesenchymal cells. It spreads most commonly through bodily fluids. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver, and rash. Treatment includes over-the-counter pain and fever medications to get relief from the symptoms of the disease.

For a complete picture of Epstein–Barr Virus (HHV-4) Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.